Stephens Issues Positive Forecast for Establishment Labs (NASDAQ:ESTA) Stock Price

Establishment Labs (NASDAQ:ESTA) had its price objective lifted by Stephens from $85.00 to $90.00 in a research report report published on Wednesday,Benzinga reports. Stephens currently has an overweight rating on the stock.

A number of other research analysts also recently issued reports on ESTA. Needham & Company LLC boosted their price target on shares of Establishment Labs from $84.00 to $86.00 and gave the stock a “buy” rating in a research report on Tuesday. JPMorgan Chase & Co. lifted their target price on shares of Establishment Labs from $71.00 to $80.00 and gave the stock an “overweight” rating in a research note on Wednesday, December 17th. Weiss Ratings restated a “sell (e+)” rating on shares of Establishment Labs in a report on Monday, December 29th. BTIG Research upped their price target on shares of Establishment Labs from $86.00 to $88.00 and gave the company a “buy” rating in a research report on Tuesday. Finally, Mizuho increased their price target on Establishment Labs from $85.00 to $90.00 and gave the stock an “outperform” rating in a report on Wednesday, December 17th. Six equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $86.29.

Establishment Labs Trading Down 1.7%

NASDAQ ESTA opened at $78.29 on Wednesday. The firm has a market capitalization of $2.28 billion, a PE ratio of -44.99 and a beta of 0.99. The business’s 50-day moving average price is $71.06 and its two-hundred day moving average price is $57.87. The company has a current ratio of 3.33, a quick ratio of 2.10 and a debt-to-equity ratio of 15.06. Establishment Labs has a 12 month low of $26.56 and a 12 month high of $83.31.

Establishment Labs (NASDAQ:ESTA) last issued its quarterly earnings data on Tuesday, February 24th. The company reported ($0.09) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.22) by $0.13. Establishment Labs had a negative return on equity of 197.22% and a negative net margin of 24.19%.The company had revenue of $64.62 million during the quarter, compared to the consensus estimate of $63.80 million. During the same period last year, the company earned ($1.19) earnings per share. The firm’s revenue was up 45.2% compared to the same quarter last year. On average, analysts expect that Establishment Labs will post -2.41 EPS for the current year.

Hedge Funds Weigh In On Establishment Labs

Several institutional investors have recently made changes to their positions in the stock. Simplify Asset Management Inc. acquired a new stake in shares of Establishment Labs in the 3rd quarter valued at about $1,555,000. Tejara Capital Ltd raised its stake in Establishment Labs by 31.2% during the 3rd quarter. Tejara Capital Ltd now owns 102,494 shares of the company’s stock worth $4,201,000 after buying an additional 24,386 shares during the period. Woodson Capital Management LP boosted its holdings in Establishment Labs by 113.3% in the third quarter. Woodson Capital Management LP now owns 480,000 shares of the company’s stock worth $19,675,000 after acquiring an additional 255,000 shares in the last quarter. Hood River Capital Management LLC grew its stake in Establishment Labs by 138.2% in the second quarter. Hood River Capital Management LLC now owns 53,124 shares of the company’s stock valued at $2,269,000 after acquiring an additional 30,825 shares during the period. Finally, Affinity Asset Advisors LLC grew its stake in Establishment Labs by 19.6% in the second quarter. Affinity Asset Advisors LLC now owns 334,863 shares of the company’s stock valued at $14,302,000 after acquiring an additional 54,863 shares during the period. Institutional investors and hedge funds own 72.91% of the company’s stock.

Key Stories Impacting Establishment Labs

Here are the key news stories impacting Establishment Labs this week:

• Positive Sentiment: Q4 results beat expectations — EST A reported EPS of ($0.09) vs. a ($0.22) consensus and revenue of $64.62M (+45% y/y). Revenue beat and margin improvement were driver-positive for sentiment. Press Release
• Positive Sentiment: 2026 revenue guidance raised — Company provided FY2026 revenue guidance of $264.0M–$266.0M and is targeting at least 25% revenue growth, signaling continued top-line momentum. MSN Article
• Positive Sentiment: Multiple analyst upgrades/price-target raises — Stephens ($85→$90, overweight), Mizuho ($90→$100, outperform), BTIG ($86→$88, buy) and Needham ($84→$86, buy) boosted targets, reflecting bullish analyst views on growth trajectory. Benzinga Analyst Rundown
• Neutral Sentiment: Leadership transition announced — Company disclosed a leadership change intended to support the next growth phase; could be positive if execution steadies but creates short-term uncertainty. Yahoo Finance
• Neutral Sentiment: Full earnings materials and call transcript available — Analysts and investors can review details and management commentary to assess margin trajectory and M&A/R&D plans. Earnings Call Transcript
• Negative Sentiment: Company remains unprofitable — EST A reported a negative net margin (~-43%) and negative ROE; consensus still models negative EPS for the fiscal year, highlighting path to consistent profitability is not yet clear. Zacks
• Negative Sentiment: Short-term selling pressure despite positives — intraday volume has spiked above average while the stock trades down, suggesting some investors are booking gains or reacting to remaining execution/earnings risk. Benzinga

About Establishment Labs

Establishment Labs Holdings Inc is a global medical technology company specializing in the design, development and manufacture of silicone gel breast implants for aesthetic and reconstructive surgery. The company’s proprietary portfolio is built around patient-focused safety, customization and innovation, offering solutions intended to enhance surgical outcomes and support clinical traceability.

The company’s flagship products fall under the Motiva® brand, which includes a range of ergonomic and round breast implants featuring SilkSurface® texturing and an embedded Q Inside® Safety microtransponder for unique implant identification.